XML 41 R28.htm IDEA: XBRL DOCUMENT v3.25.4
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2025
Income Tax Disclosure [Abstract]  
Schedule of effective income tax rate reconciliation The following tables present reconciliations of the U.S. federal statutory income tax rate of 21% to the Company’s effective income tax rate for the years ended December 31, 2025, 2024 and 2023 (dollar values in thousands):

 

Year Ended December 31, 2025

 

U.S. federal statutory income tax rate

$

(89,206

)

 

 

21.0

%

State and local income tax, net of federal (national) income tax effect

 

585

 

 

 

(0.1

)%

Foreign tax effects

 

 

 

 

%

Effect of changes in tax laws or rates enacted in the current period

 

 

 

 

%

Effect of cross-border tax laws

 

 

 

 

%

Tax credits

 

 

 

 

 

Orphan drug credit

 

(27,137

)

 

 

6.4

%

R&D credit

 

1,061

 

 

 

(0.3

)%

Changes in valuation allowances

 

114,819

 

 

 

(27.0

)%

Nontaxable or nondeductible items

 

 

 

 

 

Section 162(m) limitation

 

12,316

 

 

 

(2.9

)%

Stock-based compensation

 

(12,413

)

 

 

2.9

%

Permanent adjustments

 

113

 

 

 

%

Changes in unrecognized tax benefits

 

 

 

 

%

Other adjustments

 

447

 

 

 

(0.1

)%

Effective income tax rate

$

585

 

 

 

(0.1

)%

 

 

Year Ended December 31,

 

 

2024

 

 

2023

 

U.S. federal statutory income tax rate

 

21.0

%

 

 

21.0

%

State income taxes, net of federal benefit

 

6.7

%

 

 

8.3

%

Tax credits generated

 

14.3

%

 

 

5.7

%

Change in deferred tax asset valuation allowance

 

(45.8

)%

 

 

(38.7

)%

Stock-based compensation

 

3.6

%

 

 

3.5

%

Other

 

(0.1

)%

 

 

0.2

%

Effective income tax rate

 

(0.3

)%

 

 

%

Schedule of deferred tax assets and liabilities

Net deferred tax assets consisted of the following (in thousands):

 

 

December 31,

 

 

 

2025

 

 

2024

 

Deferred tax assets:

 

 

 

 

 

 

Net operating loss carryforwards

 

$

139,120

 

 

$

56,677

 

Capitalized research and development

 

 

103,127

 

 

 

94,002

 

Research and development tax credit carryforwards

 

 

82,361

 

 

 

52,117

 

Change in fair value of related party revenue share liability

 

 

19,284

 

 

 

4,785

 

Stock-based compensation

 

 

14,225

 

 

 

9,705

 

Other, net

 

 

4,648

 

 

 

2,714

 

Total gross deferred tax assets

 

 

362,765

 

 

 

220,000

 

Valuation allowance

 

 

(362,495

)

 

 

(220,000

)

Total net deferred tax assets

 

 

270

 

 

 

 

Deferred tax liabilities:

 

 

 

 

 

 

Other

 

 

(270

)

 

 

 

Total gross deferred tax liabilities

 

 

(270

)

 

 

 

Net deferred tax assets

 

$

 

 

$